Jefferies, Leerink and BMO to be joint bookrunning managers for deal
By Devika Patel
Knoxville, Tenn., Sept. 12 – Affimed Therapeutics BV said it priced its $56 million initial public sale of stock with an $8.4 million greenshoe. The deal was announced June 27.
The company will sell 8 million common shares at $7.00 apiece.
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are the joint bookrunning managers.
Settlement is expected Sept. 17.
Proceeds will be used for research and development activities, working capital and general corporate purposes.
The biopharmaceutical company is based in Heidelberg, Germany. The company intends to list its common stock on the Nasdaq under the symbol “AFMD.”
| Issuer: | Affimed Therapeutics BV
|
| Issue: | Common stock
|
| Amount: | $56 million
|
| Greenshoe: | $8.4 million
|
| Shares: | 8 million
|
| Price: | $7.00
|
| Warrants: | No
|
| Bookrunners: | Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp.
|
| Co-manager: | Trout Capital LLC
|
| Announcement date: | June 27
|
| Pricing date: | Sept. 12
|
| Settlement date: | Sept. 17
|
| Stock exchange: | Nasdaq: AFMD
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
